Home Cart Sign in  
Chemical Structure| 475086-01-2 Chemical Structure| 475086-01-2

Structure of Selexipag
CAS No.: 475086-01-2

Chemical Structure| 475086-01-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NS-304 is an agonist of prostacyclin IP1 receptor with Ki of 260 nM. It is used for the treatment of pulmonary arterial hypertension.

Synonyms: NS-304; ACT-293987; Uptravi.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Selexipag

CAS No. :475086-01-2
Formula : C26H32N4O4S
M.W : 496.62
SMILES Code : O=C(NS(=O)(C)=O)COCCCCN(C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1)C(C)C
Synonyms :
NS-304; ACT-293987; Uptravi.
MDL No. :MFCD10567093
InChI Key :QXWZQTURMXZVHJ-UHFFFAOYSA-N
Pubchem ID :9913767

Safety of Selexipag

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Selexipag

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Systemic sclerosis (SSc) skin fibroblasts/myofibroblasts 30 μM, 3 μM, 0.3 μM 48 hours Selexipag significantly reduced protein synthesis and gene expression of α-SMA and S100A4, and decreased protein synthesis of COL-1 and FN. PMC5932791

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Beagles Beagle model Oral 2 mg/kg Single dose To investigate the effect of quercetin on the pharmacokinetics of selexipag and its active metabolite ACT-333679 PMC8648015

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02471183 Pulmonary Arterial Hypertensio... More >>n Less << PHASE3 COMPLETED 2016-12-05 UCSD Medical Center -La Jolla,... More >> La Jolla, California, United States|UCSF Medical Center, San Francisco, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Emory University, Atlanta, Georgia, United States|Piedmont Healthcare Research Institute, Austell, Georgia, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke Unversity, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|UT Southwestern, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Sentara Cardiovascular Research Instistute, Norfolk, Virginia, United States Less <<
NCT04565990 Hypertension, Pulmonary PHASE3 COMPLETED 2023-11-10 The Republican Scientific-Prac... More >>tical Center ''Cardiology'', Minsk, 220036, Belarus|Minsk Regional Clinical Hospital, Minsk, 220143, Belarus|Sanjivani Hospitals, Ahmedabad, 380015, India|Apollo Hospitals, Chennai, 600006, India|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea Seoul St Marys Hospital, Seoul, 06591, Korea, Republic of|Institutul de pneumoftiziologie Marius Nasta, Bucuresti, 050152, Romania|Kaohsiung Veterans General Hospital, Kaohsiung, 813, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Municipal Inst. Of Dnipropetrovsk Region. Council, Dnipro, Ukraine|Health Care Municipal Institution City Clinical Hospital #13, Kharkiv, Ukraine|State Institute Of Phthisiology And Pulmonology N.A. F.G. Yanovskiy Of Ams Ukraine, Kyiv, 03680, Ukraine Less <<
NCT04914247 Non-healing Wound|Thromboangii... More >>tis Obliterans Less << AVAILABLE - -
NCT04589390 Pulmonary Hypertension|Schisto... More >>somiasis Less << PHASE2 UNKNOWN 2022-03-31 Universidade de S?o Paulo, S?o... More >> Paulo, SP, 05048000, Brazil Less <<
NCT01112306 Pulmonary Arterial Hypertensio... More >>n Less << PHASE3 COMPLETED 2021-08-26 Mobile, Alabama, United States... More >>|Phoenix, Arizona, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Torrance, California, United States|Newark, Delaware, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Carmel, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Rochester, Minnesota, United States|Chesterfield, Missouri, United States|Saint Louis, Missouri, United States|Newark, New Jersey, United States|Bronx, New York, United States|Islandia, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Bend, Oregon, United States|Portland, Oregon, United States|Doylestown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|York, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Argentina|Cordoba, Argentina|Corrientes, Argentina|Adelaide, Australia|Bedford Park, Australia|Chermside, Australia|Concord, Australia|Darlinghurst, Australia|Fitzroy, Australia|Hobart, Australia|Murdoch, Australia|New Lambton, Australia|Parkville, Australia|Graz, Austria|Vienna, Austria|Minsk, Belarus|Brussels, Belgium|Leuven, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada|Santiago De Chile, Chile|Beijing, China|Guangzhou, China|Shanghai, China|Bogota, Colombia|Praha 2, Czechia|Arhus, Denmark|Copenhagen, Denmark|Bron Cedex, France|Le Kremlin-Bicetre Cedex, France|Lille Cedex, France|Toulouse Cedex 9, France|Berlin, Germany|Dresden, Germany|Giessen, Germany|Greifswald, Germany|Hannover, Germany|Heidelberg, Germany|K?ln, Germany|Leipzig, Germany|L?wenstein, Germany|Regensburg, Germany|Alexandroupoli, Greece|Athens, Greece|Thessaloniki, Greece|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szeged, Hungary|Ahmedabad, India|Chennai, India|Hyderabad, India|Dublin, Ireland|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel-Hashomer, Israel|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Kuala Lumpur, Malaysia|Ciudad de Mexico, Mexico|Amsterdam, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Lima, Peru|Gdansk, Poland|Krakow, Poland|Otwock, Poland|?ód?, Poland|Bucuresti, Romania|Iasi, Romania|Barnaul, Russian Federation|Ekaterinburg, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|St Petersburg, Russian Federation|Tomsk, Russian Federation|Belgrade, Serbia|Singapore, Singapore|Bratislava, Slovakia|Ko?ice, Slovakia|Barcelona, Spain|Madrid, Spain|Goteborg, Sweden|Link?ping, Sweden|Umea, Sweden|Uppsala, Sweden|Basel, Switzerland|Bern, Switzerland|Genève 14, Switzerland|Lausanne, Switzerland|Kaohsiung, Taiwan|Taipei, Taiwan|Khon Kaen, Thailand|Adana, Turkey|Istanbul, Turkey|?zmir, Turkey|Dnipro, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Glasgow, United Kingdom|London, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.01mL

0.40mL

0.20mL

10.07mL

2.01mL

1.01mL

20.14mL

4.03mL

2.01mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories